Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Xbrane Biopharma

9,75 SEK

+7,18 %

Mindre end 1K følgere

XBRANE

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
+7,18 %
-9,76 %
-71,14 %
-69,78 %
-51,51 %
-56,88 %
-99,02 %
-99,02 %
-97,96 %

Xbrane Biopharma is a biotechnology company focused on the development of biosimilars and biologics. The company is researching new therapies that can improve patient outcomes and quality of life. The products are used in the treatment of prostate cancer and endometriosis, as well as rare and serious eye diseases. Xbrane Biopharma was founded in 2008 and is headquartered in Solna, Sweden.

Læs mere
Markedsværdi
200,82 mio. SEK
Aktieomsætning
967,08 t SEK
Omsætning
198,72 mio.
EBIT %
-109,66 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
20.2
2026

Årsrapport '25

5.5
2026

Delårsrapport Q1'26

5.5
2026

Generalforsamling '26

Alle
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelse24.11.2025, 16.30

Xbrane Biopharma resolves to issue 420,517 warrants to Fenja Capital II A/S under the conditional financing solution

Xbrane Biopharma
Selskabsmeddelelse19.11.2025, 07.00

XBRANE UPDATES ON TIMING FOR RESUBMISSION OF THE BLA FOR ITS RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA

Xbrane Biopharma
Pressemeddelelse4.11.2025, 12.50

Redeye: Xbrane Biopharma (Q3 update) - Headwinds have continued

Xbrane Biopharma

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse4.11.2025, 07.00

First patient included in Xdivane pivotal clinical trial

Xbrane Biopharma
Selskabsmeddelelse3.11.2025, 07.35

THE NUMBER OF SHARES AND VOTES IN XBRANE HAS CHANGED AS A RESULT OF THE PREVIOUSLY ANNOUNCED REVERSE SPLIT OF 1:125.

Xbrane Biopharma
Pressemeddelelse28.10.2025, 20.00

Xbrane publishes answers to questions received in recent days.

Xbrane Biopharma
Pressemeddelelse28.10.2025, 20.00

Siavash Bashiri sells shares to repay loan taken in connection with the 2024 rights issue, but remains a dedicated and long-term employee and shareholder

Xbrane Biopharma
Xbrane Biopharma, Webcast, Q3'25
Videopræsentation24.10.2025, 07.00

Xbrane Biopharma, Webcast, Q3'25

Xbrane Biopharma
Selskabsmeddelelse24.10.2025, 06.00

Xbrane Biopharma releases Interim Report for January-September 2025

Xbrane Biopharma
Selskabsmeddelelse20.10.2025, 06.00

XBRANE BIOPHARMA PRESENTS THE NOMINATION COMMITTEE

Xbrane Biopharma
Pressemeddelelse20.10.2025, 06.00

Invitation to presentation of Xbrane Biopharma’s interim report January – September 2025 on October 24, 2025

Xbrane Biopharma
Selskabsmeddelelse19.10.2025, 18.00

Xbrane provides Regulatory update on FDA review of its ranibizumab biosimilar candidate

Xbrane Biopharma
Selskabsmeddelelse16.10.2025, 16.05

Xbrane Biopharma enters into conditional financing solution with Fenja Capital II A/S

Xbrane Biopharma
Selskabsmeddelelse15.10.2025, 14.15

Record date for reverse share split in Xbrane Biopharma AB

Xbrane Biopharma
Selskabsmeddelelse13.10.2025, 09.45

Announcement from extra general meeting in Xbrane Biopharma AB

Xbrane Biopharma
Selskabsmeddelelse30.9.2025, 06.00

XBRANE BIOPHARMA AB (“XBRANE” OR THE “COMPANY”) HAS ACCORDING TO PREVIOUSLY ANNOUNCED INFORMATION RESOLVED TO CARRY OUT A DIRECTED ISSUE OF IN TOTAL 25,990,000 SHARES

Xbrane Biopharma
Pressemeddelelse25.9.2025, 09.39

BioStock: Video from Xbrane's presentation at BioStock Investing in Life Science – From Seed to Success

Xbrane Biopharma
Selskabsmeddelelse10.9.2025, 06.30

NOTICE OF EXTRA GENERAL MEETING IN XBRANE BIOPHARMA AB

Xbrane Biopharma
Pressemeddelelse27.8.2025, 09.56

Redeye: Xbrane Biopharma Q2 2025 - Important months ahead

Xbrane Biopharma
Xbrane Biopharma, Webcast, Q2'25
Videopræsentation26.8.2025, 07.00

Xbrane Biopharma, Webcast, Q2'25

Xbrane Biopharma
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.